Skip to main content
. Author manuscript; available in PMC: 2024 Nov 28.
Published in final edited form as: Lancet Oncol. 2023 May 1;24(5):443–456. doi: 10.1016/S1470-2045(23)00148-1

Figure 4. Secondary efficacy endpoint analysis.

Figure 4

Shaded regions represent 95% CIs. Survival curves for the abiraterone and enzalutamide trial are capped at 84 months due to shorter follow-up than in the abiraterone trial. Abiraterone refers to abiraterone acetate and prednisolone. Prostate cancer-specific survival (A, B), failure free survival (C, D) and metastatic progression free survival (E, F) in the abiraterone and abiraterone and enzalutamide trials.